Synthego is a CRISPR and genome engineering company focused on tools and services for life science research and genomic medicine. It provides synthetic RNA and gene editing solutions for biotechnology applications.
UpMarket does not offer Synthego shares. This page covers Synthego's history before its assets were sold to Perceptive Advisors.
Synthego wound down its business and sold its technology and team to Perceptive Advisors in July 2025. UpMarket does not offer Synthego shares. This page covers Synthego's earlier valuation and funding history.
Synthego sold its technology, patents and team to Perceptive Advisors in July 2025.
See how Synthego's private-market valuation changed across funding rounds before the sale.
See reported funding rounds and revenue figures on this page, with their sources.
Accredited investors can review UpMarket's current pre-IPO offerings in companies that have not yet gone public.
Pre-IPO investments are illiquid, speculative, and involve risk of total loss of capital.
| Date | Round | PPS (split-adj.) | Valuation |
|---|---|---|---|
| Feb 2022 | Series E |
Perceptive Advisors completed its acquisition of substantially all Synthego assets on July 18, 2025, after regulatory approval in June. The deal gives Synthego new ownership under a life-sciences investor managing about $7 billion in assets.
Synthego said it is entering the molecular biology and clinical diagnostic reagents market in 2026, extending beyond its CRISPR core. The company also highlighted its synthetic sgRNA manufacturing platform as a key capability across research and development workflows.
Synthego filed Chapter 11 after raising more than $450 million, with margin compression and rising interest burdens from 2020 to 2023. At filing, it had $50 million to $100 million of assets versus $100 million to $500 million of liabilities, according to the report.
Looking for companies that are still private? Browse UpMarket's pre-IPO company directory. Accredited investors only.
Browse the directory →UpMarket curates and conducts independent diligence on every investment opportunity before it reaches the platform.
We review every offering's strategy, risk management, liquidity, fees, valuation methodology, tax matters, and all third-party providers: legal counsel, auditor, administrator, and custodian.
We offer investments exclusively from disciplined managers that pursue unique strategies across an array of asset classes.
Our goal is to empower you to build a portfolio that best meets your individual investment objectives.
No. Synthego wound down its business and sold its technology, patents and team to Perceptive Advisors in July 2025. Synthego has no shares that trade, and UpMarket does not offer Synthego shares.
Synthego has no stock price. The prices shown on this page are historical private-market prices from before its assets were sold to Perceptive Advisors.
No. Synthego no longer operates as an independent company and UpMarket does not offer Synthego shares. Accredited investors interested in companies that have not yet gone public can review UpMarket's current pre-IPO offerings.
Synthego is no longer an independent operating company, so its shares are not available to buy. This page is kept for its historical funding and valuation data. UpMarket does not offer Synthego shares.
In a pre-IPO transaction, accredited investors purchase shares from existing shareholders (such as employees, early investors, or other holders) through secondary market platforms. The company itself does not issue new shares in these transactions. UpMarket facilitates these trades as a FINRA-registered broker-dealer, handling compliance, documentation, and settlement on behalf of both parties.
Synthego sold its assets to Perceptive Advisors in July 2025. What former shareholders received was set by the terms of that sale.
UpMarket does not offer Synthego shares. The minimum for most pre-IPO offerings on UpMarket is $50,000.
Synthego's last valuation was set by the sale of its assets to Perceptive Advisors. The figures on this page show its valuation history before the sale.
Synthego is a CRISPR genome engineering company providing synthetic RNA and gene-editing tools and services for life science research and genomic medicine; Perceptive closed its asset acquisition on July 18, 2025. Synthego sold its assets to Perceptive Advisors, and UpMarket does not offer its shares.